Catalio Capital Management
Overview
Catalio Capital Management is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics, and data-driven insights. The firm invests in various asset classes like private equity, private credit and public equity and employs a long bias, fundamental, bottoms-up equity and long/short strategy to invest.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| 9amHealth | May 2026 | Series B | Co-investor |
| Beacon Biosignals | Apr 2026 | Series B Extension | Co-investor |
| Imperative Care | Mar 2026 | Debt | Co-investor |
| ProSomnus, Inc. | Feb 2026 | Early Funding | Lead |
| Somethings | Feb 2026 | Series A | Lead |
Key People
George Petrocheilos
Co-Founder Managing Partner
R. Jacob Vogelstein
Co-Founder And Managing Partner
John Henry Iucker
General Partner Head Of Credit
Tom Brooks
General Partner Member Of The Investment Committee
Charlie Nettleton
Partner, Co-Head Public Equities
Isaac Ro
Partner
Jonathan Blankfein
Partner, Portfolio Manager
Olga Maltseva
Partner Head Of Operations
Matthew J. Hobson
Principal
Scott O'Sullivan
Principal, Head Trader
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
